Patents Examined by Marianne P. Allen
  • Soluble human ST-2 antibodies and assays
    Patent number: 10745484
    Abstract: Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 18, 2020
    Assignee: Critical Care Diagnostics, Inc.
    Inventor: James V. Snider
  • Anti-EGFRvIII antibodies and uses thereof
    Patent number: 10738124
    Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: August 11, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jessica R. Kirshner, Douglas MacDonald, Gavin Thurston, Joel H. Martin, Frank Delfino, Thomas Nittoli, Marcus Kelly
  • Bispecific antibodies and methods of use in ophthalmology
    Patent number: 10730938
    Abstract: Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: August 4, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Olaf Mundigl, Joerg Thomas Regula, Ralf Schumacher, Barbara Weiser
  • Chimeric fibroblast growth factor 21 proteins and methods of use
    Patent number: 10703788
    Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: July 7, 2020
    Assignee: New York University
    Inventors: Moosa Mohammadi, Regina Goetz
  • HGF preparation suitable for treatment of neurological disorders
    Patent number: 10702582
    Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 7, 2020
    Assignee: KRINGLE PHARMA INC.
    Inventors: Kazuhiro Fukuta, Hayao Inoue
  • Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
    Patent number: 10695404
    Abstract: Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1-binding protein, a ?-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 30, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu
  • FGFR3 fusion gene and pharmaceutical drug targeting same
    Patent number: 10689705
    Abstract: The FGFR-encoding gene was studied extensively with regard to its expression, hyperamplification, mutation, translocation, or such in various cancer cells. As a result, novel fusion polypeptides in which the FGFR3 polypeptide is fused with a different polypeptide were identified and isolated from several types of bladder cancer-derived cells and lung cancer cells. The use of a fusion polypeptide of the present invention as a biomarker in FGFR inhibitor-based cancer therapy enables one to avoid side effects in cancer therapy and control the therapeutic condition to produce the best therapeutic effect, thereby enabling individualized medicine.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: June 23, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshito Nakanishi, Nukinori Akiyama, Yukari Nishito
  • Anti c-Met antibodies
    Patent number: 10676535
    Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: June 9, 2020
    Assignee: argenx BVBA
    Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
  • Antibody against EGFRvIII and use thereof
    Patent number: 10669340
    Abstract: The present invention relates to an antibody or antigen-binding fragment thereof against EGFRvIII (Epidermal Growth Factor Receptor Variant III), a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or antigen-binding fragment thereof, a composition for preventing or treating cancer, which comprises the same, a composition for diagnosing cancer, which comprises the same, and a kit for diagnosing cancer, which comprise the composition for diagnosing cancer.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: June 2, 2020
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Do-Hyun Nam, Hyunkyu Park
  • Anti-marinobufagenin antibodies and uses thereof
    Patent number: 10654925
    Abstract: The present disclosure provides chimeric, humanized and human monoclonal antibodies (mAbs) and fragments thereof that specifically bind to marinobufagenin (MBG) with high affinity. The anti-MBG mAbs and fragments thereof can be used to treat MBG-associated disorders, including hypertensive disorders and fibrotic disorders, optionally in combination with an additional therapeutic agent. Furthermore, the anti-MBG mAbs and fragments thereof can be used for diagnostic purposes, including to detect MBG in biological samples and to diagnose MBG-associated disorders.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: May 19, 2020
    Assignee: CTS Biopharma LLC
    Inventors: James W. Larrick, John M. Wages, Andrew R. Mendelsohn, Vikram Sharma, Bo Yu
  • Anti amphiregulin antibodies, compositions comprising same and uses thereof
    Patent number: 10640556
    Abstract: A method of determining the suitability of a subject to a treatment with an anti-amphiregulin antibody, wherein the subject has a cancer selected from the group consisting of ovarian cancer, head and neck cancer and pancreatic cancer exhibiting resistance to chemotherapy, is provided. The method comprising analyzing in a biological sample of the subject expression level of amphiregulin, transforming growth factor alpha (TGF-alpha) and heparin-binding epidermal growth factor (HB-EGF), wherein a level of expression of the amphiregulin above a predetermined threshold and no expression of the TGF-alpha and/or the HB-EGF or an expression below a predetermined level of the TGF-alpha and/or the HB-EGF is indicative of the suitability of the subject to treatment with the anti-amphiregulin antibody. Methods for treating cancer are also provided, as well as antibodies and pharmaceutical compositions.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: May 5, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yosef Yarden, Silvia Carvalho, Moshit Lindzen
  • Chimeric fibroblast growth factor 19 proteins and methods of use
    Patent number: 10633424
    Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: April 28, 2020
    Assignee: New York University
    Inventors: Moosa Mohammadi, Regina Goetz
  • Lyophilized formulation of HGF
    Patent number: 10610569
    Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: April 7, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryo Ohori, Kanta Horie
  • Human CDR-grafted antibody and antibody fragment thereof
    Patent number: 10590203
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: March 17, 2020
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • Technology for preparation of macromolecular microspheres
    Patent number: 10583086
    Abstract: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: March 10, 2020
    Assignee: Ansun Biopharma, Inc.
    Inventors: Michael P. Malakhov, Fang Fang
  • Liquid formulation of a VEGF antagonist
    Patent number: 10576128
    Abstract: The present invention relates to liquid pharmaceutical compositions of a VEGF antagonist for intravitreal administration comprising a histidine buffer, an inorganic salt, a carbohydrate and a polysorbate.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: March 3, 2020
    Assignee: FORMYCON AG
    Inventor: Rainer Sigl
  • Angiopoietin-like 4 antibodies and methods of use
    Patent number: 10577411
    Abstract: The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: March 3, 2020
    Assignee: NOVARTIS AG
    Inventors: John Trauger, Andrei Igorevich Voznesensky
  • Treatment of cancer using a CLL-1 chimeric antigen receptor
    Patent number: 10568947
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 25, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Assays for IGFBP7 having improved performance in biological samples
    Patent number: 10562961
    Abstract: The invention provides IGFBP7 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: February 18, 2020
    Assignee: Astute Medical, Inc.
    Inventors: Ravi A. Vijayendran, Srivatsa Venkatasubbarao
  • Methods for treating idiopathic pulmonary fibrosis
    Patent number: 10555713
    Abstract: The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering anti-CTGF antibodies. Methods for prognosing individuals with IPF are also provided.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 11, 2020
    Assignee: FIBROGEN, INC
    Inventors: Seth Porter, John L. Stauffer